Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). Its product engine has generated programs for five CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis; Friedreich's ataxia; Huntington's disease, and spinal muscular atrophy. The Company's gene therapy approach uses adeno-associated virus (AAV) vectors, which are modified, non-replicating versions of AAV, and which are ideal vectors for CNS gene therapy. It is also focused on gene replacement and gene knockdown approaches. Its products are VY-AADC01 program for advanced Parkinson's disease, VY-SOD101 for a monogenic form of Amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich's ataxia, VY-HTT01 for Huntington's disease and VY-SMN101 for spinal muscular atrophy (SMA).